Kratal table. container, in a pack, 60

Storage:

active ingredients: 1 tablet contains hawthorn fruit thick extract (Crataegiaefructusextractumspissum) (3.0-3.3:1), (extractant: ethanol 70% v/v), in terms of dry substance – 43 mg, dog nettle thick extract ( Leonuriaeherbaextractumspissum) (4.5-5.6:1), (extractant: ethanol 70% v/v), in terms of dry matter – 87 mg, taurine, in terms of 100% dry matter – 867 mg;

excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silicon dioxide.

Medicinal form. Tablets.

The main physicochemical properties: oval tablets from light gray or light brown to dark brown in color, with inclusions, with a biconvex surface.

Pharmacotherapeutic group. Combined cardiology products. ATC code C01E X.

Pharmacological properties.

Pharmacodynamics.

Kratal has mild cardiotonic, antianginal, antioxidant, antiarrhythmic, antihypoxic, antiaggregant and antiatherogenic effects; inhibits the renin-angiotensin and kallikrein-kinin systems, the processes of lipid peroxidation, has a positive effect on the production of cyclic adenosine monophosphate (cAMP). Improves blood supply and the functional state of the myocardium, increases the “coronary reserve”, improves the contractile and pumping functions of the heart muscle, reduces blood pressure and normalizes the heart rate.

Kratal reduces the manifestations of digitalis intoxication. Increases work capacity, improves mood, has a calming, neuroprotective effect (eliminates somatonegative disorders – irritability, mood swings).

Pharmacokinetics.

The components of the drug are almost completely absorbed from the digestive tract. The time during which the maximum concentration of taurine and other components of the drug in the blood is reached is 2 hours. Kratal is evenly distributed in body tissues and fluids. The main amount of it is excreted in the urine, the half-life is 6-8 hours.

Clinical characteristics.

Indication.

· Neurocirculatory dystonia;

as part of combined therapy for:

– chronic ischemic heart disease;

– postradiation syndrome.

Contraindication.

Increased sensitivity to the components of the drug;

· expressed bradycardia and arterial hypotension.

Method of application and dosage.

The duration of treatment and the dose is determined by the doctor individually. Use the drug orally, 1-2 tablets 3 times a day before meals. The course of treatment is 3-4 weeks.

Children.

There is no experience of using the drug for the treatment of children.

Overdose.

Symptoms: hypersensitivity reactions, allergic reactions, dyspeptic reactions, general weakness, feeling of fatigue, dizziness, drowsiness, arterial hypotension, bradycardia.

Treatment: discontinuation of the drug and symptomatic therapy.

Adverse reactions.

Manifestations of increased sensitivity, allergic reactions (including hyperemia, rashes, itching, swelling of the skin, urticaria), dyspeptic phenomena, general weakness, increased fatigue, dizziness, drowsiness, arterial hypotension, bradycardia are possible.

In the event of the appearance of any undesirable phenomena, the patient must consult a doctor.

Expiry date. 3 years.

Do not use after the expiration date indicated on the package.

Storage conditions.

In the original packaging at a temperature not higher than 25 °C.

Keep out of the reach of children.

Packaging.

10 tablets in a blister, 2 blisters in a pack; 60 tablets in a container and a pack; 90 tablets in a container and a pack.

Release category. Without a prescription.

Producer.

Public joint-stock company “Scientific-production center “Borshchagiv Chemical-Pharmaceutical Plant”.

The location of the manufacturer and the address of the place of its activity.

Ukraine, 03134, Kyiv, str. Myru, 17